Daily Archives: September 13, 2022
RCT | Dexamethasone is not effective for the treatment of dyspnea in patients with cancer and increases the risk of adverse events.
13 Sep, 2022 | 13:22h | UTCEffect of dexamethasone on dyspnoea in patients with cancer (ABCD): a parallel-group, double-blind, randomised, controlled trial – The Lancet Oncology (free for a limited period)
Commentary on Twitter
Our phase III randomized study, published in Lancet Oncology today, showed high-dose steroid didn’t improve SOB and should not be used routinely in pts with lung ca for SOB palliation. My personal link in Lancet Oncology article ⁰https://t.co/Mj0AAzMujB pic.twitter.com/FMG7csHZsn
— Joe Y Chang (@JoeChangMD) September 7, 2022
Cluster RCT | Tighter vs. less tight glycemic targets for women with gestational diabetes mellitus for reducing maternal and perinatal morbidity.
13 Sep, 2022 | 13:21h | UTC
Dementia: evidence, experience and resources.
13 Sep, 2022 | 13:20h | UTCDementia: evidence, experience and resources – Evidently Cochrane
RCT | A double-dose influenza vaccination during hospitalization for acute coronary syndrome did not improve outcomes compared to standard-dose outpatient vaccination.
13 Sep, 2022 | 13:19h | UTC
Commentary on Twitter
In the VIP-ACS trial, among patients hospitalised with an ACS, double dose influenza vaccination before discharge does not reduce cardiovascular and pulmonary outcomes compared with standard dose vaccination ?https://t.co/L9e7MXWfWV#EHJ #ESCCongress @ehj_ed @rladeiraslopes pic.twitter.com/95o50krrwm
— European Society of Cardiology Journals (@ESC_Journals) August 31, 2022
Review / Perspective | Which patients with aortic stenosis should be referred to surgery rather than transcatheter aortic valve implantation?
13 Sep, 2022 | 13:18h | UTC
Commentary on Twitter
Which patients with aortic stenosis should be referred to surgery rather than transcatheter aortic valve implantation? https://t.co/dlNFpabAIB @escardio #EHJ #ESCYoung #cardiotwitter @ehj_ed @rladeiraslopes pic.twitter.com/FcuDNgTPxk
— European Society of Cardiology Journals (@ESC_Journals) May 16, 2022
M-A | Blood type linked to the risk of stroke before age 60.
13 Sep, 2022 | 13:17h | UTCContribution of Common Genetic Variants to Risk of Early Onset Ischemic Stroke – Neurology (link to abstract – $ for full-text)
News Releases:
Is your blood type linked to your risk of stroke before age 60? – American Academy of Neurology
Blood Type Linked To Stroke Risk Before 60 – University of Maryland
Radiological assessment of dementia | Consensus for a practical and clinically oriented guide to image acquisition, evaluation, and reporting.
13 Sep, 2022 | 13:13h | UTC
RCT | Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19.
13 Sep, 2022 | 13:16h | UTC
Commentaries on Twitter
Interesting results in the #PANAMO trial of vilobelimab, an anti-C5a antibody, in critically ill ICU patients w/ COVID19.
People on MV (n=386) randomized to vilobelimab vs placebo. Mortality was (maybe) reduced in a subgroup w/ more severe illness…?https://t.co/bO5XiRptag
1/ pic.twitter.com/EUNda67T9j— Nick Mark MD (@nickmmark) September 11, 2022
NEW Research—In addition to SOC, vilobelimab improves survival of invasive mechanically ventilated patients w/ #COVID19 and leads to a significant decrease in mortality
Read the PANAMO study from Prof Alexander Vlaar & colleagues here https://t.co/k5UuqQtqyE pic.twitter.com/Xmrb76ZpzW
— The Lancet Respiratory Medicine (@LancetRespirMed) September 8, 2022
RCT | Dipeptidyl peptidase-1 inhibition does not improve outcomes in patients hospitalized with COVID-19.
13 Sep, 2022 | 13:15h | UTC
Commentary on Twitter
NEW Research—Brensocatib treatment did not improve clinical status at day 29 in patients hospitalised with #COVID19
Being presented at #ERSCongress, ALERT 3 session, Sept 5 from 13:15 BST
From @profjdchalmers, @keirholly, @meretelong & colleagueshttps://t.co/Vlqhfs6qtj pic.twitter.com/5CY0LS4Bvy
— The Lancet Respiratory Medicine (@LancetRespirMed) September 5, 2022
Artificial liver support in patients with liver failure: a modified DELPHI consensus of international experts.
13 Sep, 2022 | 13:13h | UTC
Commentary on Twitter
Artificial liver support
? albumin dialysis
? acute failure
? decompensated cirrhosis/acute‑on‑chronic failure
? refractory pruritus
? hypoxic injury
? post‑hepatectomy failure
? graft failure post #Tx
? drug overdose
? technique/safety#FOAMcc
? https://t.co/d841FcTHEd pic.twitter.com/gO79gLs60a— Intensive Care Medicine (@yourICM) September 7, 2022
AGA Clinical practice update on the endoscopic approach to recurrent acute and chronic pancreatitis.
13 Sep, 2022 | 13:12h | UTC
Phase 2 single-arm study | Neoadjuvant Cemiplimab for stage II to IV cutaneous squamous-cell carcinoma.
13 Sep, 2022 | 13:11h | UTCNeoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Neoadjuvant Cemiplimab Induces Promising Pathologic Complete Response in CSCC – Cancer Network
Commentary on Twitter
A phase 2, multicenter study showed that four doses of neoadjuvant cemiplimab (anti–PD-1 antibody) led to a pathological complete response in 51% of patients with locally advanced cutaneous squamous-cell carcinoma. #ESMO22 https://t.co/NbICkb5kLM pic.twitter.com/a67fgxKBLy
— NEJM (@NEJM) September 12, 2022
Cohort Study | Incidence, timing, and causes of late bleeding after TAVR.
13 Sep, 2022 | 13:10h | UTCIncidence, Timing, and Causes of Late Bleeding After TAVR in an Asian Cohort – JACC: Asia
Editorial: Late Bleeding Following TAVR in Japan: An Important Cause of Mortality – JACC: Asia
Commentary: Late Bleeding Not Rare, Ups Mortality After TAVI in All-Asian Cohort: OCEAN-TAVI – TCTMD
Retrospective Cohort Study | Outcomes of partial oral antibiotic treatment for complicated S. aureus bacteremia in people who inject drugs.
13 Sep, 2022 | 13:09h | UTCOutcomes of Partial Oral Antibiotic Treatment for Complicated S. aureus Bacteremia in People Who Inject Drugs – Clinical Infectious Diseases (free PDF for a limited period)
Commentaries on Twitter
Interesting cohort study from @WashUID led by @LauraMarks5: IV–>PO antibiotics for PWID with Staph bacteremia associated with comparable outcomes to "standard of care" all IV, esp after 10 days of IV. Don't d/c all abx at time of discharge! @CIDJournal https://t.co/0rOfYSTnkH pic.twitter.com/yqCjifWAEK
— Paul Sax (@PaulSaxMD) September 6, 2022
?⚡⚡#CID @LauraMarks5
PWID w comp SA bacteremia who received oral antibiotics after an incomplete IV antibiotic(~10d) were significantly less likely to experience microbiologic failure or death than pts discharged without oral antibiotics #IDTwitter https://t.co/5zXeNfx2YL pic.twitter.com/hVhFD4iJik— Antibiotic Steward Bassam Ghanem?? (@ABsteward) September 2, 2022
Review | Acute pancreatitis: diagnosis and treatment.
13 Sep, 2022 | 13:04h | UTCAcute Pancreatitis: Diagnosis and Treatment – Drugs
Commentaries:
Evidence-Based Disposition of Acute Pancreatitis – emDocs
Pancreatitis – National Institute for Health and Care Excellence
RCT | Five-year analysis of adjuvant Pembrolizumab or placebo in stage III melanoma.
13 Sep, 2022 | 13:03h | UTCFive-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma – NEJM Evidence
Phase 2b RCT | ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis.
13 Sep, 2022 | 13:01h | UTCABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension – The Lancet Gastroenterology & Hepatology (link to abstract – $ for full-text)
Commentary on Twitter
Among patients with moderate-to-severe #ulcerativecolitis who had not responded or were intolerant to previous treatment, all three doses of obefazimod (ABX464) resulted in significantly greater reductions from baseline in modified Mayo score by week 8 vs placebo #gitwitter #IBD https://t.co/oDcQaEFVKp
— Rob Brierley (@Rob__Brierley) September 6, 2022
Levoketoconazole in the treatment of patients with endogenous Cushing’s syndrome: a double-blind, placebo-controlled, randomized withdrawal study.
13 Sep, 2022 | 13:02h | UTCRelated study: Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing’s syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial – The Lancet Diabetes & Endocrinology (link to abstract – $ for full-text)
M-A of randomized trials | High-flow nasal cannula oxygen therapy vs. non-invasive ventilation for patients with acute exacerbation of COPD after extubation.
13 Sep, 2022 | 13:00h | UTC
RCT | Sulopenem vs. Ciprofloxacin for the treatment of uncomplicated urinary tract infections in women.
13 Sep, 2022 | 13:00h | UTC
Retrospective cohort study | Tisagenlecleucel (an anti-CD19 CAR T-cell therapy) for relapsed or refractory B-cell acute lymphoblastic leukemia in infants and children younger than 3 years of age at screening.
13 Sep, 2022 | 12:59h | UTCCommentaries:
CD19 CAR T cells for infants and young children – The Lancet Haematology (free registration required)
CAR-T Therapy Effective in Youngest Kids With ALL — Analysis shows safety and outcomes equivalent to those reported in older children – MedPage Today (free registration required)
Commentary on Twitter
NEW research—tisagenlecleucel has antitumour activity and acceptable safety in young children and infants (aged younger than 3 years at screening) with B-cell ALL: results of an international, retrospective study #leusm #pedonc #tcellrx https://t.co/kdh3dW5PRU pic.twitter.com/FgQZKQWtXV
— The Lancet Haematology (@TheLancetHaem) September 8, 2022
Systematic Review | Listening to music for insomnia in adults.
13 Sep, 2022 | 12:55h | UTCListening to music for insomnia in adults – Cochrane Library
Systematic Review | Adding rapid diagnostic tests to community‐based programs for treating malaria.
13 Sep, 2022 | 12:57h | UTCAdding rapid diagnostic tests to community‐based programmes for treating malaria – Cochrane Library
Systematic Review | Ultra‐radical (extensive) surgery vs. standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer.
13 Sep, 2022 | 12:56h | UTCRelated Study: Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer – New England Journal of Medicine